...
首页> 外文期刊>Oncology letters >Expression of SDF-1 and CXCR4 transcript variants and CXCR7 in epithelial ovarian cancer
【24h】

Expression of SDF-1 and CXCR4 transcript variants and CXCR7 in epithelial ovarian cancer

机译:SDF-1和CXCR4转录变体以及CXCR7在上皮性卵巢癌中的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Chemokine stromal cell-derived factor-1 (SDF-1) and its receptors, CXCR4 and CXCR7, have been implicated in epithelial ovarian cancer progression and metastasis. However, limited data are available on the expression levels of SDF-1 and CXCR4 variants and CXCR7 in human epithelial ovarian cancer. The present study aimed to characterize the expression pattern and levels of SDF-1, CXCR4 and CXCR7 in normal human ovaries and epithelial ovarian cancer. The expression of SDF-1 and CXCR4 transcript variants and CXCR7 was determined by quantitative polymerase chain reaction (qPCR). Plasma SDF-1α levels were determined by commercially available EIA kits and cancer antigen 125 (CA 125) levels were quantified by automated microparticle enzyme immunosorbent assay. High expression levels of SDF-1 transcript variant 1 were identified in ovarian cancer and control ovaries. By contrast, in both groups the expression levels of SDF-1 transcript variants 3 and 4 were extremely low. Furthermore, SDF-1 variant 1 levels were notably higher in epithelial ovarian cancer than in control ovaries, while data for the remaining transcripts were similar in both groups. CXCR4 transcript variant 2 and CXCR7 expression levels in normal and neoplastic ovaries were similar. In both groups, CXCR4 transcript variant 2 was not detected. Plasma SDF-1α levels were notably higher in females with epithelial ovarian cancer than in the control ovaries. Elevated levels of blood SDF-1α were found prior to surgery, 6 days after surgery and following completion of the first chemotherapy course. These increases were independent of the type of epithelial ovarian cancer. Our results suggest that the expression of SDF-1 and the genes controlling alternative splicing are elevated in epithelial ovarian cancer, leading to an increased formation of SDF-1 variant 1. Elevated plasma SDF-1α levels in epithelial ovarian cancer patients are not associated with the presence of tumors and/or metastases, however reflect a general response to the disease.
机译:趋化因子基质细胞衍生因子-1(SDF-1)及其受体CXCR4和CXCR7与上皮性卵巢癌的进展和转移有关。但是,关于人类上皮性卵巢癌中SDF-1和CXCR4变体以及CXCR7的表达水平的数据有限。本研究旨在表征正常人卵巢和上皮性卵巢癌中SDF-1,CXCR4和CXCR7的表达模式和水平。通过定量聚合酶链反应(qPCR)确定SDF-1和CXCR4转录物变体和CXCR7的表达。血浆SDF-1α水平通过可商购的EIA试剂盒确定,癌症抗原125(CA 125)水平通过自动微粒酶免疫吸附测定进行定量。在卵巢癌和对照卵巢中鉴定出高表达水平的SDF-1转录变体1。相反,在两组中,SDF-1转录本变体3和4的表达水平都非常低。此外,上皮性卵巢癌中SDF-1变异1的水平显着高于对照卵巢,而两组中其余转录本的数据相似。正常卵巢和肿瘤卵巢中的CXCR4转录变体2和CXCR7表达水平相似。在两组中,均未检测到CXCR4转录变体2。患有上皮性卵巢癌的女性血浆SDF-1α水平明显高于对照组卵巢。术前,术后6天和完成第一个化学疗程后,血SDF-1α水平升高。这些增加与上皮性卵巢癌的类型无关。我们的结果表明,上皮性卵巢癌中SDF-1的表达和控制选择性剪接的基因升高,从而导致SDF-1变体1的形成增加。上皮性卵巢癌患者血浆SDF-1α的水平升高与然而,肿瘤和/或转移的存在反映了对该疾病的一般反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号